GHRP-6
GHRP-6, or growth hormone releasing peptide-6, is a lab-made peptide of six amino acids that copies part of how the hunger hormone ghrelin works. It has been studied in people as a way to prompt a short pulse of the body's own growth hormone.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 300 mcg per Peptide Dosing Protocols. All 2 sources
- 5 mg in 3 mL
How much to draw
Full calculator →Opened on 300 mcg, the figure Peptide Dosing Protocols reports for GHRP-6, and a 5 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for GHRP-6 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 300 mcg · Low: 100 mcg · High: 300 mcg | 3x daily, at least 4 hours apartnull · 8 weeks on, 4 weeks off | SubQ | Peptide Dosing ProtocolsWhat it saysHideGHRP-6 is typically dosed at 100-300 mcg per injection. |
| Cycling reference: 6-8 weeks on, 4 weeks off. Cited for appetite stimulation and GH release with fat metabolism support. | not statedOn-cycle 6-8 weeks, off-cycle 4 weeks | subcutaneous | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- 3x daily, at least 4 hours apartnull · 8 weeks on, 4 weeks off
- SubQ
- Peptide Dosing Protocols
What it saysHide
GHRP-6 is typically dosed at 100-300 mcg per injection.
- not statedOn-cycle 6-8 weeks, off-cycle 4 weeks
- subcutaneous
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- 3 mL bacteriostatic water
We have not published an audit on GHRP-6. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
GHRP-6 signals the pituitary gland to release a brief pulse of growth hormone instead of adding growth hormone from outside, and it also brings on strong hunger within minutes. Researchers link this to the ghrelin receptor (GHS-R1a), and human studies show the pulse needs intact GHRH signalling, which is the reasoning behind pairing it with a GHRH analog. Controlled human comparisons found it raises ACTH, cortisol and prolactin alongside growth hormone, unlike ipamorelin. Despite heavy marketing, there is little controlled human evidence that it produces meaningful muscle gain or fat loss on its own.
Activates the ghrelin receptor (GHS-R1a) to trigger a natural GH pulse. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: controlled human comparisons found GHRP-6 raises cortisol and prolactin as well as growth hormone, more so at higher doses. Because growth hormone affects glucose, blood sugar and insulin sensitivity can shift.
Reported by users: intense hunger within minutes of a dose, water retention or puffiness, tingling or numbness in the hands, a brief head-rush or flushing, and tiredness.
Not ruled out: repeated high doses can blunt the growth hormone response over time. Research-use vials are not tested or approved for human use, so purity and contamination are real risks.
Who should avoid it
People with diabetes or insulin resistance: growth hormone can raise blood sugar and lower insulin sensitivity.
People with active or past cancer: growth hormone and IGF-1 signalling is a theoretical concern.
People who are pregnant or breastfeeding: safety has not been established.
Competitive athletes: growth hormone secretagogues are banned by WADA and are detectable on testing.
Anyone with a complex medical history: the reference states its list is not complete and that a clinician should review history, medicines and lab work first.
What gets monitored
Track IGF-1 and fasting glucose if relevant. (reported by Peptide Dosing Protocols)
Common questions
What is GHRP-6?
GHRP-6 is a synthetic six-amino-acid peptide that activates the ghrelin receptor, which signals the pituitary to release a pulse of the body's own growth hormone. It was the first peptide of its kind, described by Cyril Bowers in 1984.
What is GHRP-6 used for?
In research it is used to study growth hormone release, and it was used as a tool to test how much growth hormone the pituitary can produce. Animal and cell work on protecting heart and other tissue is described as early and unproven in large human trials.
What doses of GHRP-6 are described in research?
Reported amounts and schedules for GHRP-6 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
GHRP-2 vs GHRP-6: what is the difference?
GHRP-2 is described as releasing more growth hormone per microgram and causing less hunger. GHRP-6 causes the strongest appetite increase in its family.
GHRP-6 vs ipamorelin: which has the cleaner profile?
Ipamorelin is usually called the cleaner option, because it releases growth hormone without meaningful effects on appetite, cortisol or prolactin. GHRP-6 raises all three.
Does GHRP-6 build muscle?
On its own, the evidence for meaningful muscle gain is weak. The growth hormone rise is described as real but modest next to injectable HGH, and results depend heavily on training, sleep and nutrition.
What are the side effects of GHRP-6?
The biggest one is intense hunger soon after a dose. Others reported include water retention, tingling or numbness in the hands, brief flushing and tiredness.
How is GHRP-6 reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Sources
- 01Bowers CY, Momany FA, Reynolds GA, Hong A On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984)
- 02Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996)
- 03Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999)
- 04Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin in humans: comparison with GHRP-6 and GHRP-2 (GH, ACTH, cortisol, prolactin). Journal of Clinical Endocrinology & Metabolism (2001)
- 05Leal-Cerro A, Pereira JL, Garcia-Luna PP, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology & Metabolism (1998)
- 06Berlanga-Acosta J, Abreu-Cruz A, Garcia-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology (2017)
- 07Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences USA (1995)
- 08Kojima M, Kangawa K Ghrelin: structure and function. Physiological Reviews (2005)
- 09World Anti-Doping Agency Prohibited List, Section S2: Peptide Hormones, Growth Factors, Related Substances (growth hormone secretagogues). WADA (2026)
- 10U.S. Food & Drug Administration Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.